To determine whether STAT3 activation in PTEN-deficient cancer cells can also limit the effects of PI3K/AKT/mTOR inhibitors, we knocked down STAT3 in the HGC-27, MDA-MB436, and 786-O cells, and treated the wild-type and knockdown cells with BEZ235. The gene discussed is AKT1; the disease is cancer.